THERAPEUTIC AGENT FOR DIABETES

PROBLEM TO BE SOLVED: To obtain a therapeutic agent having a low side effect, low toxicity and high safety by using dephostatin as an active component. SOLUTION: The objective therapeutic agent is produced by including 0.01-100 wt.% of dephostatin of the formula as an active component in the agent....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	TAKEUCHI TOMIO, UMEZAWA KAZUO, SAWA TSUTOMU, KITAHARA MIKIRO, YAMASHITA TAKASHI
Format:	Patent
Sprache:	eng
Schlagworte:	ACYCLIC OR CARBOCYCLIC COMPOUNDS CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	PROBLEM TO BE SOLVED: To obtain a therapeutic agent having a low side effect, low toxicity and high safety by using dephostatin as an active component. SOLUTION: The objective therapeutic agent is produced by including 0.01-100 wt.% of dephostatin of the formula as an active component in the agent. The daily administration rate for adult is usually 0.01-1,000 mg/kg in one or divided doses. It can be used in the form of peroral agent, injection, suppository, poultice, etc., and peroral agent is preferable from the viewpoint of the physical load on the patient. It has remarkable suppressing effect on the release of free fatty acid from cultured fat cell by epinephrine stimulation without accompanying cell damage.